Immune Checkpoint Inhibitors Trigger and Exacerbate Anti-CV2/CRMP5 Paraneoplastic Neurologic Syndromes.

Cereda GS, Villagrán-García M, Farina A, Benaiteau M, Birzu C, Sautereau A, Bayrak M, Picard G, Psimaras D, Rogemond V, Joubert B, Honnorat J.